Glycotope is a clinical stage immuno-oncology company built on world-leading glycobiology expertise. A set of our highly innovative clinical and pre-clinical projects with focus on oncology/immuno-oncology are available for partnering. The Company has a mature and growing pipeline of proprietary cancer therapies.
Our innovative GlycoExpress® technology enables the generation of high quality oncology and non-oncology candidates with fully human glycosylation improving activity, drug characteristics and side effect profiles. The GlycoBody platform generates highly specific mAbs against carbohydrate epitopes found only on tumor cells.
Glycotope is based in Berlin. The Company has a strong financial base being well supported by the existing investors including the Strüngmann Family Office.
In addition, Glycotope offers a wide range of Service in Cell Line and Process Development, Analytical development, Glycan- and Protein analysis and Clinical Immunomonitoring. For more information please visit https://www.glycotope.com/biopharmaceuticals-services/